Literature DB >> 187934

Quantitative evaluation of Epstein-Barr-virus-infected mononuclear peripheral blood leukocytes in infectious mononucleosis.

G Rocchi, A Felici, G Ragona, A Heinz.   

Abstract

We devised a quantitative assay for Epstein-Barr-virus-infected mononuclear leukocytes (virocytes) to determine their prevalence in the blood of patients with acute-phase and convalescent-phase infectious mononucleosis and in healthy Epstein-Barr-virus-seropositive controls. Mononuclear peripheral blood leukocyte suspensions were tested for virus-determined cytoproliferative activity by cocultivation with human cord-cell indicator cultures. The highest levels of virocytes among circulating mononuclear leukocytes were found in the early acute phase of infectious mononucleosis (up to 0.05 per cent). Virocytemia decreased to levels comparable with those of healthy controls (less than 0.00001 per cent) by the third month after onset of infectious mononucleosis. These findings provide a quantitative profile of the course of the infection at cellular level and support existing evidence of the efficiency of immune control mechanisms in limiting Epstein-Barr-virus infection during the course of infectious mononucleosis.

Entities:  

Mesh:

Year:  1977        PMID: 187934     DOI: 10.1056/NEJM197701202960302

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  32 in total

1.  Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells.

Authors:  Donna Hochberg; Tatyana Souza; Michelle Catalina; John L Sullivan; Katherine Luzuriaga; David A Thorley-Lawson
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

2.  Oligo-monoclonal immunoglobulins frequently develop during concurrent cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections in patients after renal transplantation.

Authors:  E Drouet; C Chapuis-Cellier; S Bosshard; C Verniol; A Niveleau; J L Touraine; J L Garnier
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 3.  Lymphocyte function and virus infections.

Authors:  A M Denman
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

Review 4.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

Review 5.  Role of donor versus recipient type Epstein-Barr virus in post-transplant lymphoproliferative disorders.

Authors:  T Haque; D H Crawford
Journal:  Springer Semin Immunopathol       Date:  1998

Review 6.  Rheumatoid arthritis--a virus disease?

Authors:  A M Denman
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1978

7.  Emergence of non-major-histocompatibility-complex-restricted lytic CD8+ cells in the blood of nasopharyngeal carcinoma patients.

Authors:  M Lakhdar; H Thameur; M Maalej; F Ben Ayed; A Ladgham
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

8.  Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis.

Authors:  G Tosato; A D Steinberg; R Yarchoan; C A Heilman; S E Pike; V De Seau; R M Blaese
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

9.  Epstein-Barr virus infection in transplant recipients: Summary of a workshop on surveillance, prevention and treatment.

Authors:  Upton Allen; Caroline Alfieri; Jutta Preiksaitis; Atul Humar; Dorothy Moore; Bruce Tapiero; Raymond Tellier; Michael Green; Dele Davies; Diane Hébert; Sheila Weitzman; Martin Petric; Kevan Jacobson
Journal:  Can J Infect Dis       Date:  2002-03

10.  Virologic Diagnosis, Viral Monitoring, and Treatment of Epstein-Barr Virus Infectious Mononucleosis.

Authors:  Hal B. Jenson
Journal:  Curr Infect Dis Rep       Date:  2004-06       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.